loading
Schlusskurs vom Vortag:
$0.8601
Offen:
$0.862
24-Stunden-Volumen:
205.19K
Relative Volume:
0.08
Marktkapitalisierung:
$1.70M
Einnahmen:
$644.60K
Nettoeinkommen (Verlust:
$-9.87M
KGV:
-0.00103
EPS:
-837.9618
Netto-Cashflow:
$-9.02M
1W Leistung:
-2.13%
1M Leistung:
-0.72%
6M Leistung:
-79.63%
1J Leistung:
-94.93%
1-Tages-Spanne:
Value
$0.86
$0.8637
1-Wochen-Bereich:
Value
$0.85
$0.93
52-Wochen-Spanne:
Value
$0.7846
$17.90

Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile

Name
Firmenname
Biodexa Pharmaceuticals Plc Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
13
Name
Twitter
Name
Nächster Verdiensttermin
2024-06-13
Name
Neueste SEC-Einreichungen
Name
BDRX's Discussions on Twitter

Vergleichen Sie BDRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
BDRX
Biodexa Pharmaceuticals Plc Adr
0.8637 4.34M 644.60K -9.87M -9.02M -837.96
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.16 120.29B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
554.58 60.26B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
339.80 43.10B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
598.89 36.65B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.94 33.09B 3.81B -644.79M -669.77M -6.24

Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-02-08 Eingeleitet Ladenburg Thalmann Buy

Biodexa Pharmaceuticals Plc Adr Aktie (BDRX) Neueste Nachrichten

pulisher
Jul 28, 2025

Biodexa advances FAP treatment with phase 3 trial initiation By Investing.com - Investing.com South Africa

Jul 28, 2025
pulisher
Jul 28, 2025

Breakthrough FAP Treatment Enters Phase 3: How Biodexa Could Transform $7B Cancer Prevention Market - Stock Titan

Jul 28, 2025
pulisher
Jul 16, 2025

Biodexa Pharmaceuticals Announces ADR Ratio Change Effective July 31, 2025 - The Globe and Mail

Jul 16, 2025
pulisher
Jul 15, 2025

Biodexa Pharmaceuticals Announces Reverse ADR Split to Regain Nasdaq Compliance - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

Biodexa Pharmaceuticals PLC Announces ADR Ratio Change Effective July 31, 2025 - Nasdaq

Jul 15, 2025
pulisher
Jul 15, 2025

Biodexa Pharmaceuticals to implement 1:10 ADR ratio change - Investing.com

Jul 15, 2025
pulisher
Jul 15, 2025

Biodexa Pharmaceuticals PLC Announces ADR Ratio Change from 1:10 to 1:100,000. - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

MFS Extends Deadline for Liquidity Event for MFS Investment Grade Municipal Trust - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

ADR Ratio Change - GlobeNewswire

Jul 15, 2025
pulisher
Jul 15, 2025

Biodexa Plans Major ADR Restructuring: 1:10 Reverse Split to Meet Nasdaq Requirements - Stock Titan

Jul 15, 2025
pulisher
Jul 14, 2025

Biodexa files European clinical trial application for FAP treatment By Investing.com - Investing.com India

Jul 14, 2025
pulisher
Jul 14, 2025

Biodexa files European clinical trial application for FAP treatment - Investing.com

Jul 14, 2025
pulisher
Jul 14, 2025

Biodexa's $20M-Backed Phase 3 Trial for Rare Cancer Prevention Drug Expands to Europe - Stock Titan

Jul 14, 2025
pulisher
Jul 14, 2025

SMX (Security Matters) Plc (SMX) Stock: Navigating Drops and Gains - investchronicle.com

Jul 14, 2025
pulisher
Jul 14, 2025

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) - GlobeNewswire

Jul 14, 2025
pulisher
Jul 09, 2025

Company’s Banking Stock: Dissecting a 60.04% Quarterly Revenue Decline Amid Growth - investchronicle.com

Jul 09, 2025
pulisher
Jun 27, 2025

Biodexa Pharmaceuticals Secures 100% Shareholder Approval for Key Corporate Decisions at AGM - Stock Titan

Jun 27, 2025
pulisher
Jun 25, 2025

Biodexa Announces Activation of First Clinical Study Site - GlobeNewswire

Jun 25, 2025
pulisher
Jun 23, 2025

Biodexa Unveils Phase 3 FAP Trial "Serenta": New Hope for Rare Disease Patients - Stock Titan

Jun 23, 2025
pulisher
Jun 18, 2025

Biodexa enrolls first patient in type 1 diabetes drug trial - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Breakthrough Oral Diabetes Drug Enters Phase 2 Trial, Could Replace Daily Insulin Injections for Millions - Stock Titan

Jun 18, 2025
pulisher
Jun 13, 2025

Biodexa Pharmaceuticals changes share nominal value By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Biodexa Pharmaceuticals changes share nominal value - Investing.com

Jun 13, 2025
pulisher
Jun 11, 2025

Biodexa shareholders approve all resolutions at general meeting By Investing.com - Investing.com India

Jun 11, 2025
pulisher
Jun 11, 2025

Biodexa shareholders approve all resolutions at general meeting - Investing.com

Jun 11, 2025
pulisher
Jun 04, 2025

Phase 2 Trial Begins: Biodexa's Breakthrough Type 1 Diabetes Drug Shows Promise in Human Cells - Stock Titan

Jun 04, 2025
pulisher
May 22, 2025

Biodexa secures additional $3M for cancer drug trial By Investing.com - Investing.com India

May 22, 2025
pulisher
May 22, 2025

BDRXBiodexa Pharmaceuticals plc Latest Stock News & Market Updates - Stock Titan

May 22, 2025
pulisher
May 22, 2025

Biodexa secures additional $3M for cancer drug trial - Investing.com

May 22, 2025
pulisher
May 20, 2025

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here - sharewise

May 20, 2025
pulisher
May 20, 2025

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Nasdaq

May 20, 2025
pulisher
May 15, 2025

Biodexa Pharmaceuticals adjusts warrant exercise price - Investing.com

May 15, 2025
pulisher
May 15, 2025

Biodexa Pharmaceuticals adjusts warrant exercise price By Investing.com - Investing.com India

May 15, 2025
pulisher
May 12, 2025

Biodexa gains orphan drug status in EU for colon disease treatment - Investing.com

May 12, 2025
pulisher
May 12, 2025

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP - GlobeNewswire

May 12, 2025
pulisher
May 02, 2025

Biodexa Special Resolution Falls 4% Short: Chairman Promises New Fundraising Proposals - Stock Titan

May 02, 2025
pulisher
Apr 24, 2025

What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock - MSN

Apr 24, 2025
pulisher
Apr 17, 2025

Biodexa Shareholders to Vote on Strategic Share Subdivision Plan: Key Meeting Details Revealed - Stock Titan

Apr 17, 2025
pulisher
Apr 11, 2025

Preliminary Results for the Year Ended 31 December 2024 - GlobeNewswire

Apr 11, 2025
pulisher
Mar 19, 2025

Biodexa Pharmaceuticals advances FAP treatment trial By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Biodexa Pharmaceuticals advances FAP treatment trial - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter - BioSpace

Mar 19, 2025
pulisher
Mar 10, 2025

Biodexa gets FDA nod for Phase 3 eRapa study in FAP - Investing.com India

Mar 10, 2025
pulisher
Mar 10, 2025

FDA Clears Biodexa's Phase 3 Protocol for Rare Disease Drug eRapa - Stock Titan

Mar 10, 2025
pulisher
Mar 07, 2025

Why Plus Therapeutics, Inc. (PSTV) Soared on Thursday - Yahoo Finance

Mar 07, 2025
pulisher
Mar 06, 2025

Biodexa selects Precision as CRO for eRapa Phase 3 study in Europe - Investing.com

Mar 06, 2025
pulisher
Feb 12, 2025

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status - Barchart

Feb 12, 2025
pulisher
Feb 11, 2025

Biodexa Pharmaceuticals Plc ADR [BDRX] Is Currently 31.94 above its 200 Period Moving Avg: What Does This Mean? - The DBT News

Feb 11, 2025
pulisher
Feb 10, 2025

why Teva- Pharmaceutical Industries Ltd. ADR [TEVA] is a Good Choice for Investors After New Price Target of $24.71 - The DBT News

Feb 10, 2025
pulisher
Feb 10, 2025

Palantir Technologies Inc [PLTR] Is Currently -0.39 below its 200 Period Moving Avg: What Does This Mean? - The DBT News

Feb 10, 2025
pulisher
Feb 10, 2025

Biodexa Pharmaceuticals Plc ADR (BDRX) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle

Feb 10, 2025

Finanzdaten der Biodexa Pharmaceuticals Plc Adr-Aktie (BDRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$77.55
price up icon 0.23%
$37.12
price down icon 0.40%
$105.18
price up icon 0.17%
$26.66
price down icon 0.30%
$110.05
price down icon 1.28%
biotechnology ONC
$299.94
price down icon 1.90%
Kapitalisierung:     |  Volumen (24h):